Cross-Taper Protocol from Sertraline to Fluvoxamine for OCD
Rationale for the Switch
- Higher SSRI doses are necessary for OCD compared to depression or anxiety disorders, with greater efficacy at higher doses 1
Critical Safety Considerations
- The overlap period creates potential for serotonin syndrome, particularly when combining SSRIs, monitor closely for symptoms such as fever, confusion, agitation, tremor, hyperreflexia, myoclonus, diaphoresis, and tachycardia 2
- Benzodiazepines, such as alprazolam and triazolam, may require dose reduction due to fluvoxamine's potent CYP1A2 inhibition and moderate CYP3A4 inhibition 2
Expected Timeline for Response
- Assess therapeutic benefit at 12 weeks minimum, as OCD requires prolonged treatment duration at effective doses 1
- If inadequate response at 300mg after 12 weeks, consider augmentation strategies rather than further dose escalation 1